Abstract
Reduced structural network connectivity is proposed as a biomarker for chronic schizophrenia. This study assessed regional morphometric similarity as an indicator of cortical inter-regional connectivity, employing longitudinal normative modeling to evaluate whether decreases are consistent across individuals with schizophrenia. Normative models were trained and validated using data from healthy controls (n = 4310). Individual deviations from these norms were measured at baseline and follow-up, and categorized as infra-normal, normal, or supra-normal. Additionally, we assessed the change over time in the total number of infra- or supra-normal regions for each individual. At baseline, patients exhibited reduced morphometric similarity within the default mode network compared to healthy controls. The proportion of patients with infra- or supra-normal values in any region at both baseline and follow-up was low (<6%) and similar to that of healthy controls. Mean intra-group changes in the number of infra- or supra-normal regions over time were minimal (<1) for both the schizophrenia and control groups, with no significant differences observed between them. Normative modeling with multiple timepoints enables the identification of patients with significant static decreases and dynamic changes of morphometric similarity over time and provides further insight into the pervasiveness of morphometric similarity abnormalities across individuals with chronic schizophrenia.
| Original language | English |
|---|---|
| Article number | 70 |
| Number of pages | 10 |
| Journal | Schizophrenia |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 24 Apr 2025 |
Bibliographical note
Publisher Copyright:© The Author(s) 2025.
Funding
Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (PI16/02012, PI17/01249, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI22/01621, PI23/00625), financed by the European Union - NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Project COllaborative Network for European Clinical Trials For Children “c4c” (Grant agreement No 777389) Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET), Award Number 5P50MH115846-03 (Project FEP-CAUSAL) and AwardNumber 1R01MH128971-01A1 (Project SZ-aging), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The authors thank Yasser Alemán-Goméz, Alberto Fernández Pena, Zimbo Boudewijns, and Joyce van Baaren for code and technical assistance.